PTX Media related, page-750

I kind of disagree.

You have the TF deal, where a huge company with deep expertise that is going to fund and do research to help make the tech scale.

You have the largest cancer institute wanting to partner with flagship tech from one of their flagship programs. They also have mountains of historical data and world leading clinical and research expertise.

And then there is Prescient. Not even hit the clinic yet. How many organisations invest money and time in an innocuous company on the other side of the world at this early stage? Some pretty in the know people must feel they are onto something.

Finally, lots of people would be whinging if they went direct to instos for the CR. You can't have it both ways. If you want to be involved next time they raise cash, then get in on it now, but if it's under-subscribed and they skip retail next time, we will all have a fair idea why.